BCYC241220P20000
- 5.60
- +2.80+100.00%
Bicycle Therapeutics Newsroom
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $33
Bicycle Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Bicycle Therapeutics Price Target Cut to $33.00/Share From $55.00 by HC Wainwright & Co.
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)
Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Maintains Target Price $30
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $32
ADRs End Higher; WISeKey International Holding Ltd. Climbs 139%
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump
Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk
B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17
Bicycle Therapeutics Down Over 35%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely
Express News | Bicycle Therapeutics PLC: Dose Selection and Topline Data From Phase 2/3 Duravelo-2 Trial Planned for 2H 2025
Express News | Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene Amplification
Bicycle Therapeutics Expands Clinical Advisory Board With Three Distinguished Global Oncology Experts